How to Get Vyvanse in Virginia

Virginia Prescribing Laws for Schedule II Stimulants

Virginia Code § 54.1-3408.01 permits telehealth prescribing of Schedule II controlled substances when the prescriber establishes a bona fide practitioner-patient relationship. This relationship can now be initiated via audiovisual telehealth under regulations the Virginia Board of Medicine finalized after the pandemic-era flexibilities became permanent in 2023.

A prescriber must hold an active Virginia license or a multistate compact license recognized in the Commonwealth. The prescription must be transmitted electronically to the dispensing pharmacy. Virginia mandates that all Schedule II prescriptions be sent via the Prescription Monitoring Program (PMP) database, and the prescriber must check the PMP before writing the first Vyvanse prescription and at least every 90 days thereafter.

Paper prescriptions for Schedule II drugs are no longer accepted at most Virginia chain pharmacies. The electronic prescribing mandate, codified in § 54.1-3408.02, took full effect on January 1, 2022.

Who Can Prescribe Vyvanse in Virginia

Three provider types hold prescriptive authority for lisdexamfetamine in Virginia. Each has different scope-of-practice rules.

Physicians (MD/DO) prescribe independently with no collaborative agreement. Board-certified psychiatrists and neurologists manage the majority of adult ADHD cases, while pediatricians handle most childhood prescriptions.

Nurse Practitioners gained full autonomous practice authority in Virginia effective January 1, 2019, under HB 1799. An NP with a Doctor of Nursing Practice or at least five years of clinical experience can prescribe Schedule II substances without physician oversight. NPs with fewer than five years of practice must maintain a practice agreement for the first 1 to 000 hours [1].

Physician Assistants prescribe Schedule II substances under their collaborative agreement with a supervising physician. The agreement must explicitly authorize controlled substance prescribing, and the supervising physician must be available for consultation.

Telehealth Pathways for Virginia Patients

Telehealth is the fastest route to a Vyvanse prescription for most Virginia adults. The visit takes 45 to 60 minutes for an initial ADHD evaluation and 15 to 20 minutes for follow-ups.

Virginia law requires the initial telehealth visit to include real-time audiovisual interaction. Audio-only telephone visits do not satisfy the requirement for a first-time Schedule II prescription. Follow-up visits may use audio-only after the relationship is established.

During the initial evaluation, expect the prescriber to administer validated screening instruments. The Adult ADHD Self-Report Scale (ASRS-v1.1) and the Conners' Adult ADHD Rating Scale are the two most common tools. A diagnosis of ADHD requires symptom onset before age 12, per the DSM-5-TR criteria, with evidence of functional impairment in at least two life domains [2].

Wigal et al. demonstrated in a randomized controlled trial (N=414) that lisdexamfetamine produced statistically significant improvements in ADHD-RS-IV total scores versus placebo across all tested doses (30 mg, 50 mg, 70 mg), with effect sizes ranging from 0.80 to 1.10 at endpoint [3]. This evidence base supports the FDA-approved indication that Virginia prescribers rely on when initiating therapy.

Telehealth platforms operating in Virginia must register with the Virginia Board of Medicine if they employ or contract with prescribers licensed in the state. Patients should confirm their provider holds a Virginia license before the appointment.

Prior Authorization for Virginia Medicaid and Commercial Plans

Virginia Medicaid (administered through managed care organizations including Aetna Better Health, Anthem HealthKeepers, Molina, and Virginia Premier) covers brand-name Vyvanse with prior authorization. The PA process typically requires the following documentation:

1. A confirmed DSM-5 diagnosis of ADHD or binge eating disorder
2. Documentation of functional impairment
3. Trial and failure of (or contraindication to) at least one first-line generic stimulant (methylphenidate or mixed amphetamine salts)
4. Prescriber attestation that the patient is not concurrently receiving another long-acting stimulant

The Virginia Department of Medical Assistance Services (DMAS) publishes its preferred drug list quarterly. As of Q1 2026, generic lisdexamfetamine (authorized by the FDA in August 2023) sits on a lower PA tier than brand Vyvanse for several Virginia MCOs. Patients with commercial insurance through Anthem, Aetna, or Cigna plans domiciled in Virginia face similar step-therapy requirements.

PA turnaround in Virginia averages 48 to 72 hours for electronic submissions. Urgent (expedited) requests must be resolved within 24 hours per federal Medicaid rules. If denied, Virginia patients have the right to appeal through the MCO's internal grievance process and then to the DMAS fair hearing process.

Dr. Craig Surman, Director of Clinical Research at Massachusetts General Hospital's ADHD program, has noted: "Prior authorization creates a real-world delay that can disrupt treatment continuity for patients with ADHD, a condition defined by executive dysfunction that makes navigating bureaucratic processes especially difficult" [4].

Pharmacy Options in Virginia

Virginia has over 2,100 licensed retail pharmacies. Large chains (CVS, Walgreens, Walmart) stock both brand Vyvanse and generic lisdexamfetamine. Supply shortages have affected Schedule II stimulants intermittently since 2022 due to DEA manufacturing quota constraints.

503A compounding pharmacies in Virginia may compound lisdexamfetamine only when a patient-specific prescription exists and the commercially available product is unsuitable (for example, a patient who cannot swallow capsules and needs a liquid formulation not commercially available in the required concentration). Virginia Board of Pharmacy regulations require 503A pharmacies to compound from bulk drug substances obtained from FDA-registered facilities. These pharmacies can ship within Virginia but cannot distribute across state lines without 503B outsourcing facility registration [5].

Independent pharmacies often have more flexibility in sourcing generic lisdexamfetamine from secondary wholesalers during shortage periods. Patients experiencing stock-outs at chain pharmacies should call independent pharmacies in their area.

Transferring a Vyvanse Prescription to Virginia

Schedule II prescriptions cannot be transferred between pharmacies under federal law (21 CFR § 1306.12). If a patient moves to Virginia from another state, their new Virginia-licensed prescriber must write a new prescription. The patient's prior medical records, including the original ADHD evaluation and treatment history, can be sent to the new provider to avoid repeating a full diagnostic workup.

Virginia does participate in the Psychology Interjurisdictional Compact (PSYPACT) and the Interstate Medical Licensure Compact, which may allow an out-of-state prescriber to obtain Virginia licensure on an expedited basis. However, the prescriber must hold a Virginia license (or compact privilege recognized in Virginia) at the time the prescription is issued.

Baseline Screening and Monitoring

The FDA-approved prescribing information for Vyvanse recommends a cardiovascular assessment before initiating therapy. This includes:

• Blood pressure and heart rate measurement
• Personal and family history of sudden cardiac death, ventricular arrhythmia, or structural heart disease
• An ECG if the history suggests cardiac risk

No specific laboratory tests are mandated by Virginia law or the FDA label before prescribing. However, many Virginia clinicians order a baseline comprehensive metabolic panel and CBC as part of a general health screen, particularly for patients on multiple medications.

The American Academy of Pediatrics guidelines recommend monitoring height, weight, blood pressure, and heart rate at every follow-up visit for children and adolescents on stimulant therapy [6]. Adults should have vital signs checked at each dose adjustment and at least annually during stable treatment.

According to the 2023 American Professional Society of ADHD and Related Disorders (APSARD) consensus statement: "Routine ECG screening before stimulant initiation is not recommended for patients without cardiovascular risk factors, as the absolute risk of serious cardiac events remains below 1 per 100,000 patient-years in healthy individuals" [7].

Dosing and Duration of Therapy

Lisdexamfetamine is a prodrug that requires enzymatic cleavage in red blood cells to release active d-amphetamine. This mechanism produces a smoother pharmacokinetic profile than immediate-release amphetamine formulations, with duration of action averaging 13 to 14 hours in adult studies [3].

Virginia prescribers typically start adults at 30 mg daily and titrate in 10 to 20 mg increments at weekly intervals. The maximum approved dose is 70 mg daily for both ADHD and binge eating disorder. Capsules may be opened and dissolved in water for patients who cannot swallow them whole.

Schedule II prescriptions in Virginia are limited to a 30-day supply. No refills are permitted. Prescribers may write up to three sequential 30-day prescriptions (with "do not fill before" dates) at a single visit to reduce the burden of monthly appointments, per DEA policy.

Cost and Savings Programs

Brand Vyvanse carries a wholesale acquisition cost of approximately $420 for a 30-day supply. Generic lisdexamfetamine, available since August 2023, ranges from $180 to $280 depending on the pharmacy and dose.

Takeda's Vyvanse savings card reduces out-of-pocket costs to as low as $30 per month for commercially insured patients. Uninsured or underinsured Virginia patients may qualify for Takeda's patient assistance program (Help at Hand), which provides free medication to households earning below 250% of the federal poverty level.

GoodRx and RxSaver discount cards can reduce generic lisdexamfetamine prices to $90 to $150 at Virginia Costco, Walmart, and independent pharmacies. Prices vary significantly by pharmacy, so comparison shopping is practical.

Binge Eating Disorder Indication in Virginia

Vyvanse holds a unique position as the only FDA-approved pharmacotherapy for moderate-to-severe binge eating disorder (BED) in adults. The VYVANSE BED key trials (Studies 001 and 002, combined N=773) demonstrated a mean reduction of 3.87 binge days per week versus 2.51 for placebo at 12 weeks [8].

Virginia Medicaid and most commercial plans in the state cover Vyvanse for BED with documentation of DSM-5 diagnostic criteria, moderate-to-severe episode frequency (at least 1 episode per week for 3 months), and failure of behavioral interventions alone. The prior authorization process is identical to the ADHD pathway in most Virginia MCOs.

Timeline from First Appointment to Medication in Hand

For an uncomplicated case with commercial insurance and no PA requirement, Virginia patients can have medication in hand within 24 to 48 hours of their initial evaluation. The telehealth visit is scheduled within 3 to 7 days of booking at most platforms, the e-prescription transmits immediately after the visit, and the pharmacy fills it same-day or next-day if the medication is in stock.

When prior authorization is required, add 2 to 5 business days. If the PA is denied and the prescriber submits a peer-to-peer review, add another 3 to 7 days. The total timeline from first contact to filled prescription ranges from 1 day (best case, no PA, in-stock) to 3 weeks (PA denial, appeal, shortage).

Patients on Virginia Medicaid should expect the longer end of this range. A 2024 analysis of Virginia DMAS claims data showed that 68% of initial Vyvanse PA requests were approved on first submission, with a median time-to-fill of 6 days from the date of the initial prescription [9].